Form 4: Seres Therapeutics Executive Sells Shares After Stock Unit Vesting

Matthew R. Henn, Chief Scientific Officer of Seres Therapeutics, sold 927 shares of common stock after the vesting of restricted stock units.

Summary

• Matthew R. Henn, Chief Scientific Officer of Seres Therapeutics, executed transactions involving the company's stock.
• On November 15, 2024, 2,812 restricted stock units vested and converted into common stock.
• Following the vesting, Mr. Henn sold 927 shares of common stock on November 18, 2024, at a weighted average price of $0.5407 per share.
• The sales were executed under a pre-arranged Rule 10b5-1 trading plan adopted on April 13, 2023, to cover taxes related to the vesting of the restricted stock units.
• After these transactions, Mr. Henn directly owns 77,770 shares of Seres Therapeutics common stock.

Sentiment

Score: 5

Explanation: The document reflects a routine transaction by an executive, not indicative of any positive or negative sentiment towards the company's performance.

Industry Context

This is a routine transaction for executives who receive stock-based compensation. The use of a 10b5-1 plan is common to avoid accusations of insider trading.

Comparison to Industry Standards

• The use of Rule 10b5-1 trading plans is a standard practice among publicly traded companies to allow insiders to sell shares without concerns about insider trading.
• Many biotech companies use stock options and restricted stock units as part of their compensation packages, similar to Seres Therapeutics.
• The sale of shares by executives after vesting is a common occurrence and does not necessarily indicate a negative outlook for the company.

Stakeholder Impact

• The sale of shares by an executive may have a minor impact on shareholder sentiment, but it is a common occurrence and not necessarily indicative of a negative outlook.

Key Dates

Keywords

Seres Therapeutics, insider trading, stock sale, restricted stock units, Rule 10b5-1, Matthew R. Henn, MCRB